![Patrick Schlegel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Patrick Schlegel
Director/Miembro de la Junta en Biosceptre (Aust) Pty Ltd. .
Origen de la red de primer grado Patrick Schlegel.
Entidad | Tipo de entidad | Industria | |
---|---|---|---|
Biosceptre (Aust) Pty Ltd.
![]() Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia.
3
| Holding Company | Pharmaceuticals: Major | 3 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Patrick Schlegel a través de su red personal
Empresa | Sector | Personas relacionadas | Puesto principal |
---|---|---|---|
GRESHAM TECHNOLOGIES PLC | Packaged Software | President | |
Prescare
![]() Prescare Miscellaneous Commercial ServicesCommercial Services Prescare provides care services including residential, in-home community care and chaplaincy and pastoral care. It offers residential and dementia care, affordable housing, day therapy centre, respite care and social programs. The company is headquartered in Milton, Australia. | Miscellaneous Commercial Services | Director/Board Member | |
Project Better Energy Ltd.
![]() Project Better Energy Ltd. Electric UtilitiesUtilities Project Better Energy Ltd. is a British company that generates electric power. The private company is based in Burton-on-Trent, UK. and has subsidiaries in United Kingdom. Project Better Energy was founded in 2012. | Electric Utilities | Director/Board Member | |
Biosceptre International Ltd.
![]() Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Biotechnology | Chairman Director/Board Member Chief Executive Officer |
Estadísticas
Internacional
Reino Unido | 4 |
Australia | 2 |
Sectorial
Technology Services | 2 |
Commercial Services | 2 |
Utilities | 2 |
Health Technology | 2 |
Operativa
Director/Board Member | 7 |
Chairman | 2 |
Chief Executive Officer | 2 |
President | 1 |
Founder | 1 |
Las relaciones más conectadas
Insiders | |
---|---|
Andrew Walton-Green | 4 |
Currie Gavin | 3 |
Michael Lovett | 2 |
- Bolsa de valores
- Insiders
- Patrick Schlegel
- Conexiones Empresas